Amantadine hydrochloride is under clinical development by Shinkei Therapeutics and currently in Phase II for Traumatic Brain Injury. According to GlobalData, Phase II drugs for Traumatic Brain Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Amantadine hydrochloride LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amantadine hydrochloride overview
Amantadine hydrochloride (MR-301) is under development for the treatment of traumatic brain injury. It is administered through intravenous route as solution and acts by targeting NMDA (N-Methyl-D-Aspartate) receptor.
Shinkei Therapeutics overview
Shinkei Therapeutics is a pharmaceutical company developing drugs for the treatment of central nervous system disorders. Its pipeline products include MR-101, a VMAT2 inhibitor for Huntington’s disease (HD); MR-201, a formulation of NMDA-antagonist to prevent pseudobulbar affect (PBA); MR-301, an NMDA-antagonist for traumatic brain injury; and MR-401, a novel formulation for the treatment of amyotrophic lateral sclerosis (ALS) symptoms. The company seeks to work in partnership with other pharmaceutical companies for out-licensing and strategic alliance opportunities. Shinkei Therapeutics is headquartered in Princeton, New Jersey, the US.
For a complete picture of Amantadine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
